These alterations, in turn, can engage host BA receptors like Farnesoid X Receptor (FXR) and Takeda G protein-coupled Receptor 5 (TGR5/GPBAR1) on immune and cancer cells, thereby influencing anti-tumor immune responses and the efficacy of treatments such as immune checkpoint inhibitors (ICIs). This evidence concerns the gene GPBAR1 and neoplasm.